Breaking News, Collaborations & Alliances

Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

Program aimed to deliver early-stage clinical supply of plasmid DNA for drug substance manufacturing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, entered an agreement to manufacture starting materials critical to clinical-stage research. Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features, a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters